NYSE:WAT - Waters Stock Price, Price Target & More

Waters trades on the New York Stock Exchange (NYSE) under the ticker symbol "WAT."

Waters announced that its Board of Directors has initiated a stock buyback program on Tuesday, April 24th 2018, which permits the company to repurchase $3,000,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization permits the company to repurchase up to 18.2% of its shares through open market purchases. Shares repurchase programs are typically a sign that the company's management believes its stock is undervalued.

Waters Co. (NYSE:WAT) posted its quarterly earnings data on Tuesday, April, 24th. The medical instruments supplier reported $1.59 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.55 by $0.04. The medical instruments supplier had revenue of $530.70 million for the quarter, compared to the consensus estimate of $534.17 million. Waters had a net margin of 1.14% and a return on equity of 25.80%. The company's revenue for the quarter was up 6.6% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.46 earnings per share. View Waters' Earnings History.

Waters is scheduled to release their next quarterly earnings announcement on Tuesday, July, 24th 2018. View Earnings Estimates for Waters.

Waters issued an update on its FY18 earnings guidance on Tuesday, April, 24th. The company provided earnings per share (EPS) guidance of $8.10-8.30 for the period, compared to the Thomson Reuters consensus estimate of $8.19.

17 analysts have issued twelve-month price targets for Waters' shares. Their forecasts range from $180.00 to $230.00. On average, they expect Waters' share price to reach $206.5333 in the next year. View Analyst Ratings for Waters.

Some companies that are related to Waters include Illumina (ILMN), Agilent Technologies (A), Mettler-Toledo International (MTD), Bio-Rad Laboratories, Inc. Class A Common Stock (BIO), Bio-Rad Laboratories, Inc. Class B (BIO.B), PerkinElmer (PKI), Integra Lifesciences (IART), Bruker (BRKR), Coherent (COHR), Horiba (HRIBF), Accelerate Diagnostics (AXDX), Pacific Biosciences of California (PACB), Quanterix (QTRX), Fluidigm (FLDM) and Harvard Bioscience (HBIO).

Media headlines about WAT stock have been trending somewhat negative on Sunday, according to Accern Sentiment Analysis. The research firm identifies positive and negative press coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Waters earned a daily sentiment score of -0.18 on Accern's scale. They also assigned news coverage about the medical instruments supplier an impact score of 46.38 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the next several days.

Waters' stock is owned by a number of of retail and institutional investors. Top institutional investors include BlackRock Inc. (7.20%), Massachusetts Financial Services Co. MA (6.33%), Baillie Gifford & Co. (3.29%), Veritas Asset Management LLP (2.50%), Northern Trust Corp (1.38%) and Franklin Resources Inc. (1.14%). Company insiders that own Waters stock include Arthur G Caputo, Christopher A Kuebler, David Terricciano, Elizabeth B Rae, Eugene G Cassis, Ian King, Joann A Reed, Laurie H MD Glimcher, Mark T Beaudouin, Michael C Harrington, Michael F Silveira, Michael J Berendt, Rohit Khanna, Terrence P Kelly, Thomas P Salice and William J Miller. View Institutional Ownership Trends for Waters.

WAT stock was sold by a variety of institutional investors in the last quarter, including Massachusetts Financial Services Co. MA, Veritas Asset Management LLP, Baillie Gifford & Co., Schroder Investment Management Group, Boston Partners, Millennium Management LLC, Swiss National Bank and American Century Companies Inc.. Company insiders that have sold Waters company stock in the last year include Christopher A Kuebler, David Terricciano, Elizabeth B Rae, Eugene G Cassis, Joann A Reed, Mark T Beaudouin, Michael C Harrington, Michael F Silveira, Rohit Khanna, Terrence P Kelly, Thomas P Salice and William J Miller. View Insider Buying and Selling for Waters.

WAT stock was purchased by a variety of institutional investors in the last quarter, including Frontier Capital Management Co. LLC, Citigroup Inc., Bamco Inc. NY, Summit Trail Advisors LLC, JPMorgan Chase & Co., Royal Bank of Canada, Ontario Teachers Pension Plan Board and Champlain Investment Partners LLC. View Insider Buying and Selling for Waters.

Shares of WAT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of WAT stock can currently be purchased for approximately $193.87.

Waters has a market capitalization of $15.12 billion and generates $2.31 billion in revenue each year. The medical instruments supplier earns $20.31 million in net income (profit) each year or $7.49 on an earnings per share basis. Waters employs 7,000 workers across the globe.

Waters' mailing address is 34 MAPLE STREET, MILFORD MA, 01757. The medical instruments supplier can be reached via phone at 508-478-2000 or via email at [email protected]